CDC's ACIP adult recommendations for Prevnar 13®

The information below represents the CDC’s ACIP recommendations to complete the pneumococcal vaccination sequence for immunocompetent adults aged 65 and older1,2
As stated by the CDC’s ACIP:
  • For adults aged ≥65 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants, the recommended interval between Prevnar 13® followed by Pneumovax® 23 is ≥8 weeks.1
  • The 2 vaccines (Prevnar 13® and Pneumovax® 23) should not be coadministered. If a dose of Pneumovax® 23 is inadvertently given earlier than the recommended interval, the dose need not be repeated.1
Prior receipt of Pneumovax® 23 within 1 year results in diminished immune responses to Prevnar 13® compared to Pneumovax® 23-naive individuals.4
Pneumovax is a registered trademark of Merck & Co., Inc.
ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; IPD=invasive pneumococcal disease.
In accordance with the CDC's ACIP recommendations for adults aged 65 and older, administer both Prevnar 13® and Pneumovax® 23 to help protect against pneumococcal pneumonia and IPD1
The CDC’s ACIP recommends Prevnar 13® in series with Pneumovax® 23 for immunocompromised patients aged 19 and older with the following medical conditions:5
  • Congenital or acquired immunodeficiencies*
  • Human immunodeficiency virus (HIV)
  • Chronic renal failure
  • Nephrotic syndrome
  • Leukemia
  • Lymphoma
  • Hodgkin disease
  • Generalized malignancy
  • Iatrogenic immunosuppression
  • Solid organ transplant
  • Multiple myeloma
  • Functional or anatomic asplenia (including sickle cell disease/other hemoglobinopathies and congenital or acquired asplenia)
  • Cerebrospinal fluid leaks
  • Cochlear implants
  • A second dose of Pneumovax® 23 is recommended (≥8 weeks after a dose of Prevnar 13® and 5 years after the most recent dose of Pneumovax® 23) for persons aged 19-64 years with functional or anatomic asplenia (including sickle cell disease/other hemoglobinopathies and congenital or acquired asplenia) and for persons with immunocompromising conditions5
  • Additionally, those who received Pneumovax® 23 before age 65 for any indication should receive another dose of Pneumovax® 23 at age 65 or later if at least 5 years have elapsed since their previous Pneumovax® 23 dose5
For complete ACIP recommendations published October 12, 2012, visit the CDC Morbidity and Mortality Weekly Report website at www.cdc.gov/mmwr.5
IMPORTANT PRESCRIBING INFORMATION FOR PREVNAR 13®
  • Individuals with altered immunocompetence, including those at higher risk for invasive pneumococcal disease (eg, individuals with congenital or acquired splenic dysfunction, HIV infection, malignancy, hematopoietic stem cell transplant, nephrotic syndrome), may have reduced antibody responses to immunization with Prevnar 13®4
  • Immunogenicity data for Prevnar 13® in adults who are at high risk for pneumococcal disease are limited to individuals with HIV infection or with a hematopoietic stem cell transplant. The effectiveness in these and other high-risk populations is not established4
  • The appropriate use of Prevnar 13® in adults with immunocompromising conditions should be based on a risk/benefit assessment by the practitioner for the individual patient
  • Prior receipt of Pneumovax® 23 within 1 year results in diminished immune responses to Prevnar 13® compared to Pneumovax® 23-naive individuals4
Pneumovax is a registered trademark of Merck & Co., Inc.
ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention.